U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2Ag.S
Molecular Weight 247.801
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SILVER SULFIDE

SMILES

[S--].[Ag+].[Ag+]

InChI

InChIKey=XUARKZBEFFVFRG-UHFFFAOYSA-N
InChI=1S/2Ag.S/q2*+1;-2

HIDE SMILES / InChI

Molecular Formula Ag
Molecular Weight 107.8682
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula HS
Molecular Weight 33.073
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.drugs.com/monograph/silver-nitrate.html | https://www.ncbi.nlm.nih.gov/pubmed/18245232

Silver iodide is an inorganic compound with the formula AgI. It is used as a photosensitive agent in photography, as a local antiseptic, as a chemical intermediate, and in cloud seeding for rain-making. The major hazards encountered in the use and handling of silver iodide stem from its toxicologic properties. Effects from exposure may include skin rashes, conjunctivitis, argyria (a permanent ashen-gray discoloration of skin, conjunctiva, and internal organs), headache, fever, hypersensitivity, laryngitis, and bronchitis.

Originator

Sources: Vestsi Akademii Navuk BSSR, Seryya Khimichnykh Navuk, Issue 2, Pages 69-73, Journal, 1990https://www.ncbi.nlm.nih.gov/pubmed/20429870
Curator's Comment: The medical uses of silver date back to at least the time of Hippocrates

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Advantage Arrest Silver Diamine Fluoride

Approved Use

Unknown
Primary
Advantage Arrest Silver Diamine Fluoride

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Curative
Unknown

Approved Use

Unknown
Curative
Unknown

Approved Use

Unknown
Primary
Colloidal silver iodide

Approved Use

Solution containing 5 to 49% of colloidal silver iodide have been employed in the treatment of infections of the mucous membranes. Ointments, usually containing 5%, have been used in inflammatory conditions of the eye, ear, and nose.
Primary
Colloidal silver iodide

Approved Use

Solution containing 5 to 49% of colloidal silver iodide have been employed in the treatment of infections of the mucous membranes. Ointments, usually containing 5%, have been used in inflammatory conditions of the eye, ear, and nose.
Palliative
Unknown

Approved Use

Antiseptic Wound Cauterization
Primary
Unknown

Approved Use

Prophylaxis of gonococcal ophthalmia neonatorum. AAP recommends use of topical silver nitrate, povidone-iodine, or possibly erythromycin for prophylaxis of nongonococcal nonchlamydial conjunctivitis in neonates, ideally administered shortly after birth.
PubMed

PubMed

TitleDatePubMed
Lack of genotoxicity of silver iodide in the SCE assay in vitro, in vivo, and in the Ames/microsome test.
1998
A chemically intelligent antimicrobial coating for urologic devices.
2000 Feb
New disinfection and sterilization methods.
2001 Mar-Apr
Comparative efficacy of hand hygiene agents in the reduction of bacteria and viruses.
2005 Mar
Photocatalytic degradation of pathogenic bacteria with AgI/TiO2 under visible light irradiation.
2007 Apr 24
Antibacterial activity and mechanism of action of the silver ion in Staphylococcus aureus and Escherichia coli.
2008 Apr
Topical antimicrobials for burn wound infections.
2010 Jun
Development of silica-coated silver iodide nanoparticles and their biodistribution.
2012 Dec
Cleaning and decontamination efficacy of wiping cloths and silver dihydrogen citrate on food contact surfaces.
2012 Jul
A novel silver iodide metalo-drug: experimental and computational modelling assessment of its interaction with intracellular DNA, lipoxygenase and glutathione.
2014 Apr 22
UCSF Protocol for Caries Arrest Using Silver Diamine Fluoride: Rationale, Indications and Consent.
2016 Jan
An alternate technique of care using silver fluoride followed by stannous fluoride in the management of root caries in aged care.
2016 Mar-Apr
Directional growth of Ag nanorod from polymeric silver cyanide: A potential substrate for concentration dependent SERS signal enhancement leading to melamine detection.
2017 Aug 5
The antifungal effects and mechanical properties of silver bromide/cationic polymer nano-composite-modified Poly-methyl methacrylate-based dental resin.
2017 May 8
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Toxicity data
Topical as a 1:80 dilution (30 ppm ionic silver).
Route of Administration: Topical
10 mkl volume of undiluted human norovirus 20% faecal suspension was mixed with 90 mkl of SDC (Silver Dihydrogen Citrate) for various contact times (15, 30, 60, 120, 300, 600 and 1800 s). At each sampling time point, 20 mkl of this solution was added to 180 mkl of 10% solution of Dey/Engley (D/E) neutralizing broth (Thermo Fisher Scientific, Waltham, MA). Samples were aliquoted and frozen at -80°C prior to nucleic acid extraction.
Substance Class Chemical
Created
by admin
on Fri Dec 15 19:47:31 UTC 2023
Edited
by admin
on Fri Dec 15 19:47:31 UTC 2023
Record UNII
9ZB10YHC1C
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SILVER SULFIDE
MI  
Systematic Name English
SILVER SULFIDE [MI]
Common Name English
Code System Code Type Description
WIKIPEDIA
SILVER SULFIDE
Created by admin on Fri Dec 15 19:47:31 UTC 2023 , Edited by admin on Fri Dec 15 19:47:31 UTC 2023
PRIMARY
PUBCHEM
166738
Created by admin on Fri Dec 15 19:47:31 UTC 2023 , Edited by admin on Fri Dec 15 19:47:31 UTC 2023
PRIMARY
CAS
21548-73-2
Created by admin on Fri Dec 15 19:47:31 UTC 2023 , Edited by admin on Fri Dec 15 19:47:31 UTC 2023
PRIMARY
MERCK INDEX
m9939
Created by admin on Fri Dec 15 19:47:31 UTC 2023 , Edited by admin on Fri Dec 15 19:47:31 UTC 2023
PRIMARY Merck Index
DAILYMED
9ZB10YHC1C
Created by admin on Fri Dec 15 19:47:31 UTC 2023 , Edited by admin on Fri Dec 15 19:47:31 UTC 2023
PRIMARY
FDA UNII
9ZB10YHC1C
Created by admin on Fri Dec 15 19:47:31 UTC 2023 , Edited by admin on Fri Dec 15 19:47:31 UTC 2023
PRIMARY
RXCUI
1549110
Created by admin on Fri Dec 15 19:47:31 UTC 2023 , Edited by admin on Fri Dec 15 19:47:31 UTC 2023
PRIMARY RxNorm
EPA CompTox
DTXSID80893679
Created by admin on Fri Dec 15 19:47:31 UTC 2023 , Edited by admin on Fri Dec 15 19:47:31 UTC 2023
PRIMARY
ECHA (EC/EINECS)
244-438-2
Created by admin on Fri Dec 15 19:47:31 UTC 2023 , Edited by admin on Fri Dec 15 19:47:31 UTC 2023
PRIMARY
MESH
C013251
Created by admin on Fri Dec 15 19:47:31 UTC 2023 , Edited by admin on Fri Dec 15 19:47:31 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE